SEC Filing Summary: BioDrain Medical, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for BioDrain Medical, Inc., a development-stage company incorporated in Minnesota. The report covers the three-month period ended March 31, 2010. The company develops an environmentally safe system for the collection and disposal of infectious fluids from surgical procedures (Fluid Management System or "FMS"). The company received FDA 510(k) clearance on April 1, 2009, and achieved its first billable shipment in June 2009. Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and a stockholders' deficit.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | YTD Inception (2002-2010) |
|---|---|---|---|
| Revenue | $288 | $0 | $16,025 |
| Net Loss | $(751,504) | $(1,005,464) | $(6,780,872) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.12) | $(2.55) |
| Cash and Cash Equivalents | $40,612 | $124,057 | N/A |
| Restricted Cash in Escrow | $67,833 | $103,333 | N/A |
| Total Current Assets | $112,969 | $139,503 | N/A |
| Total Current Liabilities | $1,647,443 | $1,444,371 | N/A |
| Stockholders' Deficit | $(2,487,511) | $(2,342,031) | $(6,780,872) |
| Net Cash Used in Operating Activities | $(295,278) | $(336,456) | $(2,848,668) |
| Net Cash Provided by Financing Activities | $319,258 | $(3,325) | $3,044,033 |
Debt and Liquidity: As of March 31, 2010, the company held $213,620 in current long-term debt and $50,000 in current convertible debt. Total long-term debt (net of discounts) was $118,371. The company has a significant liability for equity-linked financial instruments of $984,851. Accounts payable stood at $808,759.
Material Changes vs. Prior Period
- Revenue: The company recorded $288 in revenue for Q1 2010, compared to $0 in Q1 2009. This revenue was derived from disposable supplies purchased by a beta site customer.
- Net Loss: Net loss decreased by approximately $254,000 (25%) from Q1 2009 to Q1 2010. This improvement was largely driven by a gain of $112,549 on the valuation of equity-linked financial instruments in Q1 2010, compared to a loss of $496,502 in the same period in 2009.
- Expenses:
- General and Administrative (G&A): Increased significantly to $712,135 from $266,905. This was primarily due to a $527,000 increase in stock-based consulting expenses for consultants engaged to raise funds and manage investor relations.
- Operations Expense: Decreased to $64,735 from $124,313, attributed to reduced consulting and testing costs following FDA clearance.
- Sales and Marketing: Decreased to $73,052 from $102,879 due to reduced trade show and marketing supply expenses.
- Debt: The company incurred $200,000 in new convertible debt in January 2010. Additionally, a $10,000 convertible debenture with Andcor Companies, Inc. is currently in default, though the holder has verbally agreed to wait for additional funding.
Guidance, Outlook, and Risks
Capital Needs and Fundraising: Management estimates a need for approximately $3 million in capital for the next 12 months to fund operations and market launch. An investment banker was hired in January 2010 to raise $3-$5 million. As of March 31, 2010, the company had raised approximately $287,000 in 2010 but failed to meet an interim target of $500,000. Management plans to close a larger round within 30 days of the filing date. There is substantial doubt regarding the ability to raise this capital.
Outlook: The company expects to commence significant shipments of FMS units once sufficient financing is secured to pay contract manufacturers. Revenue is expected to increase significantly upon successful fundraising. Without additional capital, the company may be forced to reduce expenditures or cease operations.
Risks and Contingencies:
- Going Concern: Recurring losses and a stockholders' deficit raise substantial doubt about the company's ability to continue as a going concern.
- Liquidity: Cash on hand ($40,612) is insufficient to meet obligations beyond the second quarter of 2010 without new financing.
- Legal Proceedings: A former officer, Gerald Rice, filed a lawsuit in Minnesota state court alleging breach of contract and unpaid wages exceeding $100,000. The company denies the allegations and is defending the claim.
- Dilution: Future equity financing will likely result in substantial dilution to existing shareholders.
- Debt Default: The $10,000 Andcor debenture is in default and could be called at any time, straining liquidity.
Key Facts for Investor Verification
- Capital Runway: Verify the status of the fundraising efforts initiated in January 2010. The company explicitly states it has sufficient funds only through the end of Q2 2010.
- Debt Obligations: Confirm the status of the $10,000 Andcor debenture (currently in default) and the $200,000 convertible notes issued in January 2010.
- Legal Exposure: Monitor the outcome of the lawsuit filed by former officer Gerald Rice regarding unpaid wages and breach of contract.
- Revenue Realization: Assess the timeline for converting FDA clearance into significant commercial revenue, noting that current revenue ($288) is negligible and dependent on external financing for manufacturing.
- Equity Dilution: Review the terms of outstanding warrants (8.5 million shares) and options (1.6 million shares) which could significantly dilute existing shareholders upon exercise or conversion.